Glucagon-Like Peptide-1 Receptor Agonists and the Eye: Ocular Safety, Retinal Outcomes, and Clinical Implications
- 1Department of Anesthesiology and Pain Medicine, Bundang Jesaeng General Hospital, Daejin Medical Center, Seongnam, Korea .
- 2Department of Ophthalmology, CHA Bundang Medical Center, CHA University, Seongnam, Korea .
Abstract
Glucagon-like peptide-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity, but rapidly expanding use has generated concern about ocular adverse events. In Korea, newly established national health insurance reimbursement criteria for injectable semaglutide (Ozempic prefilled pen) took effect on February 1, 2026; as use among eligible patients may expand, proportionate ophthalmic preparedness is timely. This structured narrative review evaluates randomized trials, systematic reviews, large pharmacoepidemiologic studies, mechanistic investigations, and regulatory assessments through June 30, 2026. The evidence does not support a single class-wide syndrome of ocular toxicity. The most coherent retinal signal is early worsening of diabetic retinopathy during rapid glycemic improvement, particularly in eyes with substantial pre-existing disease; available trial and real-world evidence does not demonstrate a uniform sustained toxic effect. Nonarteritic anterior ischemic optic neuropathy is a rare but clinically important semaglutide safety signal. Multiple observational studies and regulatory action justify vigilance, although effect estimates remain heterogeneous and the absolute risk is low. Evidence for neovascular age-related macular degeneration is conflicting, whereas reported associations with retinal vein occlusion and glaucoma remain exploratory. For retina specialists, management should be phenotype based: identify active or advanced diabetic retinopathy, avoid delaying indicated retinal treatment, document the timing and trajectory of metabolic change, and urgently evaluate sudden painless visual loss or field defects. This approach preserves the substantial systemic benefits of incretin therapy while improving recognition of uncommon but consequential ocular events.
Related
- Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness
- Glucagon-like peptide-1 receptor agonists in diabetic patients with heart failure with reduced ejection fraction - real world outcomes
- Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists
- Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis
- Panniculectomy With Umbilical Transposition in the Era of Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss Modality on Postoperative Outcomes.
BibTeX
@article{yeo2026glucagonlike,
title = {{Glucagon-Like Peptide-1 Receptor Agonists and the Eye: Ocular Safety, Retinal Outcomes, and Clinical Implications}},
author = {Gwi Eun Yeo and Joonhyung Kim},
journal = {Journal of Korean medical science},
year = {2026},
month = oct,
doi = {10.3346/jkms.2026.41.e345},
url = {https://europepmc.org/article/PMC/PMC13730651},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Glucagon-Like Peptide-1 Receptor Agonists and the Eye: Ocular Safety, Retinal Outcomes, and Clinical Implications
AU - Gwi Eun Yeo
AU - Joonhyung Kim
PY - 2026
DA - 2026/10/14
JO - Journal of Korean medical science
DO - 10.3346/jkms.2026.41.e345
UR - https://europepmc.org/article/PMC/PMC13730651
AB - Glucagon-like peptide-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity, but rapidly expanding use has generated concern about ocular adverse events. In Korea, newly established national health insurance reimbursement criteria for injectable semaglutide (Ozempic prefilled pen) took effect on February 1, 2026; as use among eligible patients may expand, proportionate ophthalmic preparedness is timely. This structured narrative review evaluates randomized trials, systematic reviews, large pharmacoepidemiologic studies, mechanistic investigations, and regulatory assessments through June 30, 2026. The evidence does not support a single class-wide syndrome of ocular toxicity. The most coherent retinal signal is early worsening of diabetic retinopathy during rapid glycemic improvement, particularly in eyes with substantial pre-existing disease; available trial and real-world evidence does not demonstrate a uniform sustained toxic effect. Nonarteritic anterior ischemic optic neuropathy is a rare but clinically important semaglutide safety signal. Multiple observational studies and regulatory action justify vigilance, although effect estimates remain heterogeneous and the absolute risk is low. Evidence for neovascular age-related macular degeneration is conflicting, whereas reported associations with retinal vein occlusion and glaucoma remain exploratory. For retina specialists, management should be phenotype based: identify active or advanced diabetic retinopathy, avoid delaying indicated retinal treatment, document the timing and trajectory of metabolic change, and urgently evaluate sudden painless visual loss or field defects. This approach preserves the substantial systemic benefits of incretin therapy while improving recognition of uncommon but consequential ocular events.
SN - 1598-6357
SN - 1011-8934
ER -